Robert Rosenson, MD Email Robert Rosenson
- PROFESSOR | Medicine, Cardiology
- Cardiovascular Disease
- Hospital Affiliation
- The Mount Sinai Hospital
Robert S. Rosenson, MD
FACC, FACP, FAHA, FNLA, FACCP (inactive)
Robert S. Rosenson, MD, is Professor of Medicine at the Icahn School of Medicine at Mount where he serves as Director of Cardiometabolic Disorders. He is a Fellow of the American Heart Association Council on Epidemiology and Prevention, Fellow of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology, Fellow of the National Lipid Association and a past Fellow of the American College of Chest Physicians (inactive). He has been the recipient of a number of awards and honors, including the Ground-Breaking Doctors Award from Chicago magazine. Dr. Rosenson is Co-Editor-In-Chief, Cardiovascular Drugs and Therapy, effective February 1, 2016 and has been elected to the European Academy of Sciences.
Dr. Rosenson earned his medical degree from Tulane University in New Orleans, Louisiana where he conducted research on prostaglandin metabolism in coronary arteries. This work was recognized when he was awarded the Querens-Rives-Shore Award for best thesis in Cardiology. He then served his residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. He later completed a fellowship in cardiovascular medicine at the University of Chicago that was followed by an additional year of training as a Research Associate in lipoprotein metabolism.
Dr. Rosenson is a Diplomate of the American Board of Internal Medicine, with a subspecialty in cardiovascular disease, the National Board of Medical Examiners, and National Lipid Association. He currently serves on a number of committees for professional societies. He has served on nine committees for the American College of Cardiology, and he served as a member of the Expert Document Committee for the American College of Cardiology and ACCF Representative to the ADA Aspirin Therapy in Diabetes Position Statement. He has been extensively involved with the National Lipid Association where he serves a National Board Member and Northeast Lipid Association Board Member. Dr. Rosenson served as Co-Chair for the task force on HDL biology, and he is the current Chair of the Statin Safety Expert Muscle Document Committee. Dr. Rosenson led three international working groups on HDL that resulted in seminal articles on HDL nomenclature, HDL and macrophage cholesterol, and HDL functionality.
Dr. Rosenson has been involved in numerous grant-supported research investigations studying the effects of lipid-lowering therapy, hypoglycemic therapy, and antihypertensive agents in inflammation, thrombogenesis, and rheology. His laboratory was the first to demonstrate that statins reduce pro-inflammatory cytokine production. He has continued this work through mechanistic studies on inflammatory markers with studies on fenofibrate. Most recently, he has conducted research with selective inhibitors of inflammatory pathways such as lipoprotein-associated phospholipase A2, and secretory phospholipase A2. He has made important contributions concerning the prognostic significance of lipoprotein subclasses in coronary atherosclerosis, cardiovascular events and prediction of type 2 diabetes. He has served as Principal Investigator on a number of NIH-funded research studies, pharmaceutical-sponsored drug trials, and multicenter studies. He served as Global Principal Investigator of the PLASMA I, PLASMA II and FRANCIS trials. He has authored 230 peer-review journal articles, and nearly 600 book chapters, abstracts, and electronic publications for Up To Date Medicine.
American Board of Internal Medicine
- Cardiovascular Disease
- General Cardiology
- Heart Attack/Acute Coronary Syndrome
- Heart Disease
- Hyperlipidemia/High Cholesterol
- Metabolic Syndrome
- Type 2 Diabetes
MD, Tulane University
Residency, Internal Medicine
Brigham and Women's Hospital, Harvard Medical School
University of Chicago Hospitals
EnglishDownload the CV
Simon Dack Award for Outstanding Scholarship
American College of Cardiology
Rosenson RS, Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. European heart journal 2012 Dec; 33(23).
Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. Journal of lipid research 2012 Sep; 53(9).
Rosenson RS, Brewer HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012 Apr; 125(15).
Rosenson RS, Brewer HB, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clinical chemistry 2011 Mar; 57(3).
Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams LA. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2011 Feb; 25(1).
Rosenson RS, Elliott M, Stasiv Y, Hislop C. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. European heart journal 2011 Apr; 32(8).
Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes care 2010 Jun; 33(6).
Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 2010 Nov; 213(1).
Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring, Md.) 2009 Mar; 17(3).
Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA : the journal of the American Medical Association 1998 May; 279(20).
Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999 Mar; 353(9157).
Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009 Feb; 119(7).
Rosenson RS, Hislop C, McConnell D, Elliott M, Stasiv Y, Wang N, Waters DD. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet 2009 Feb; 373(9664).
Rosenson RS. Treatment with aspirin and dipyridamole is more effective than aspirin in reducing low shear blood viscosity. Microcirculation (New York, N.Y. : 1994) 2008 Oct; 15(7).
Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes care 2009 Jun; 32(6).
Smith SC, Anderson JL, Cannon RO, Fadl YY, Koenig W, Libby P, Lipshultz SE, Mensah GA, Ridker PM, Rosenson R. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. Circulation 2004 Dec; 110(25).
Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. Journal of the American College of Cardiology 2010 Sep; 56(14).
Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis?. The Lancet infectious diseases 2006 Apr; 6(4).
Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, Miller P, Palmer M, Sosef F. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007 Oct; 194(2).
Smith SC, Milani RV, Arnett DK, Crouse JR, McDermott MM, Ridker PM, Rosenson RS, Taubert KA, Wilson PW. Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation 2004 Jun; 109(21).
Rosenson RS, Wolff D, Green D, Boss AH, Kensey KR. Aspirin. Aspirin does not alter native blood viscosity. Journal of thrombosis and haemostasis : JTH 2004 Feb; 2(2).
Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. The American journal of cardiology 2002 Jul; 90(2).
Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010 May; 59(5).
Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. The Lancet infectious diseases 2007 May; 7(5).
Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. Journal of the American College of Cardiology 1993 Sep; 22(3).
Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes care 2007 Aug; 30(8).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Rosenson during 2018 and/or 2019. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- CVS Caremark
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Kowa Pharmaceuticals America, Inc.
Scientific Advisory Board:
- Amgen Inc.
- Eli Lilly and Company
- Regeneron Pharmaceuticals
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.